InflaRx N.V. (NASDAQ:IFRX) announces that dosing is underway in a randomized clinical trial evaluating IFX-1 in patients with severe COVID-19-induced pneumonia.
It says IFX-1 is a monoclonal anti-human
complement factor C5a antibody designed to induce an anti-inflammatory
response by blocking the biological activity of C5a.
Shares up 24% after hours.
https://seekingalpha.com/news/3556994-inflarx-doses-first-covidminus-19-ifxminus-1-shares-up-24-after-hours
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.